Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia.

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Coopervision, Inc.
ClinicalTrials.gov Identifier:
NCT01917110
First received: August 2, 2013
Last updated: March 25, 2014
Last verified: March 2014
  Purpose

The purpose of the study is to quantify the effectiveness of CooperVision MiSight® (omafilcon A) soft (hydrophilic) contact lens in slowing the rate of progression of juvenile-onset myopia.


Condition Intervention Phase
Myopia
Device: omafilcon A
Device: Spectacle
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia, Not Pathological, Aged 8-12 Years Randomized Clinical Trial.

Resource links provided by NLM:


Further study details as provided by Coopervision, Inc.:

Primary Outcome Measures:
  • Change in the spherical equivalent refractive error relative to baseline. [ Time Frame: Baseline, 1 week, 1 month, 6 months, 12 months, 18 months, 24 months ] [ Designated as safety issue: No ]
  • Change in axial length relative to baseline. [ Time Frame: Baseline, 1 week, 1 month, 6 months, 12 months, 18 months, 24 months ] [ Designated as safety issue: No ]
  • Measurement of corneal curvature (keratometry)relative to baseline. [ Time Frame: Baseline, 1 week, 1 month, 6 months, 12 months, 18 months, 24 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Measurement of pupil diameter relative to baseline. [ Time Frame: Baseline, 1 week, 1 month, 6 months, 12 months, 18 months, 24 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 78
Study Start Date: September 2013
Estimated Study Completion Date: May 2017
Estimated Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: omafilcon A
Contact Lens Group
Device: omafilcon A
Active Comparator: Spectacle Group
Prescription at Baseline
Device: Spectacle

  Eligibility

Ages Eligible for Study:   8 Years to 12 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Prior to being considered eligible to participate in this study, each subject MUST:

    1. Be between 8 and 12 years of age inclusive at the baseline examination.
    2. Have:

      1. read the Informed Assent,
      2. been given an explanation of the Informed Assent,
      3. indicated an understanding of the Informed Assent and
      4. signed the Informed Assent Form.
    3. Have their parent or legal guardian:

      1. read the Informed Consent,
      2. been given an explanation of the Informed Consent,
      3. indicated an understanding of the Informed Consent and
      4. signed the Informed Consent Form.
    4. Along with their parent or guardian, be capable of comprehending the nature of the study, and be willing and able to adhere to the instructions set forth in this protocol.
    5. Along with their parent or guardian, agree to maintain the visit schedule and be able to keep all appointments as specified in the study protocol for the duration of the study
    6. Agree to accept either the control or test lens as assigned by the randomisation scheme.
    7. Agree to wear the assigned contact lenses for a maximum of 15 hours per day, , for the duration of the 2 year study and to inform the study investigator if this schedule is interrupted. (Wearing time may be modified by the study staff for health reasons.)
    8. Possess wearable and visually functional eyeglasses.
    9. Be in good general health, based on his/her and parent's/guardian's knowledge.
    10. Have best-corrected visual acuity by manifest refraction of +0.10 logMAR (20/25 Snellen equivalent) or better in each eye.
    11. Meet the following refractive criteria determined by cycloplegic autorefraction at baseline:

      1. Spherical Equivalent Refractive Error (SERE): between -0.75 and -4.00 D inclusive.
      2. Astigmatism: < -0.75 D
      3. Anisometropia: < 1.00D

Exclusion Criteria:

  • Subjects may not be considered eligible if ANY of the following apply:

    1. Subject has previously or currently wears contact lenses or rigid gas permeable contact lenses, including orthokeratology lenses.
    2. Subject appears to exhibit poor personal hygiene (that in the investigator's opinion might prevent safe contact lens wear).
    3. Subject is currently or prior to this study has been an active participant in another clinical study.
    4. Parent / guardian or close relative is a member, of the office staff, including the investigator(s).
    5. Current or prior use of bifocals, progressive addition lenses, atropine, pirenzepine or ANY other myopia control treatment.
    6. Subject was born earlier than 30 weeks or weighed less than 1500g (3.3lb) at birth.
    7. Regular use of ocular medications (prescription or over-the-counter), artificial tears, or wetting agents.
    8. Current use of systemic medications which may significantly affect contact lens wear, tear film production, pupil size, accommodation or refractive state. Such as, but not limited to: long term use of nasal decongestants (for example, pseudoephedrine, phenylephrine), antihistamines (for example, chlorpheniramine, diphenhydramine), Prednisolone or Ritalin (methylphenidate).
    9. A known allergy to fluorescein, benoxinate, proparacaine or tropicamide.
    10. A history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, ocular viral or fungal infections or other recurrent ocular infections.
    11. Strabismus by cover test at far (4 m) or near (40 cm) wearing distance correction.
    12. Known ocular or systemic disease such as, but not limited to: anterior uveitis or iritis, episcleritis or scleritis, glaucoma, Sjogren's syndrome, lupus erythematosus, scleroderma, or diabetes.
    13. Any ocular, systemic or neuro-developmental conditions that could influence refractive development. Such as, but not limited to: persistent pupillary membrane, vitreous hemorrhage, cataract, corneal scarring, ptosis eyelid hemangiomas, Marfan's Syndrome, Down's syndrome, Ehler's-Danlos syndrome, Stickler's syndrome, ocular albinism, retinopathy of prematurity.
    14. Keratoconus or an irregular cornea.
    15. Biomicroscope findings that would contraindicate contact lens wear including, but not limited to:

      1. corneal scars within the visual axis
      2. neovascularisation or ghost vessels > 1.5 mm in from the limbus
      3. Any active anterior segment ocular disease that would contraindicate contact lens wear.
      4. giant papillary conjunctivitis of Grade 2 or worse
      5. allergic or seasonal conjunctivitis (if the study investigator believes it could significantly interfere with maintaining the specified contact lens wearing schedule)
      6. clinically significant (Grade 3 or 4) abnormalities of the anterior segment, lids, conjunctiva, sclera or associated structures.
    16. The investigator for any reason considers that it is not in the best interest of the subject to participate in the study.
    17. Have pathological myopia To be eligible to begin the study, a subject must have ALL of the inclusion criteria and NONE of the exclusion criteria present.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01917110

Locations
Spain
Departamento de Óptica y Optometría de la Universidad Europea de Madrid
Madrid, Spain
Sponsors and Collaborators
Coopervision, Inc.
Investigators
Principal Investigator: Cesar Villa Collar, PhD Departamento de Optica y Optometria de la Universidad Europea de Madrid
  More Information

No publications provided

Responsible Party: Coopervision, Inc.
ClinicalTrials.gov Identifier: NCT01917110     History of Changes
Other Study ID Numbers: P2013/05
Study First Received: August 2, 2013
Last Updated: March 25, 2014
Health Authority: Spain: Agencia Española de Medicamentos y Productos Sanitarios

Additional relevant MeSH terms:
Myopia
Refractive Errors
Eye Diseases

ClinicalTrials.gov processed this record on April 17, 2014